Downregulation of RPL6 by siRNA Inhibits Proliferation and Cell Cycle Progression of Human Gastric Cancer Cell Lines by Wu, Qiong et al.
Downregulation of RPL6 by siRNA Inhibits Proliferation
and Cell Cycle Progression of Human Gastric Cancer Cell
Lines
Qiong Wu
1., Yawen Gou
1,2., Qiaomin Wang
2, Haifeng Jin
1, Lina Cui
1, Yongguo Zhang
1, Lijie He
1, Jingbo
Wang
1, Yongzhan Nie
1, Yongquan Shi
1*, Daiming Fan
1*
1State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, the Fourth Military Medical University, Xi’an, Shaanxi, China, 2Department of Digestive
Diseases, The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui Province, China
Abstract
Our previous study revealed that human ribosomal protein L6 (RPL6) was up-regulated in multidrug-resistant gastric cancer
cells and over-expression of RPL6 could protect gastric cancer from drug-induced apoptosis. It was further demonstrated
that up-regulation of RPL6 accelerated growth and enhanced in vitro colony forming ability of GES cells while down-
regulation of RPL6 exhibited the opposite results. The present study was designed to investigate the potential role of RPL6
in therapy of gastric cancer for clinic. The expression of RPL6 and cyclin E in gastric cancer tissues and normal gastric
mucosa was evaluated by immunohistochemisty. It was found that RPL6 and cyclin E were expressed at a higher level in
gastric cancer tissues than that in normal gastric mucosa and the two were correlative in gastric cancer. Survival time of
postoperative patients was analyzed by Kaplan- Meier analysis and it was found that patients with RPL6 positive expression
showed shorter survival time than patients that with RPL6 negative expression. RPL6 was then genetically down-regulated
in gastric cancer SGC7901 and AGS cell lines by siRNA. It was demonstrated that down-regulation of RPL6 reduced colony
forming ability of gastric cancer cells in vitro and reduced cell growth in vivo. Moreover, down-regulation of RPL6 could
suppress G1 to S phase transition in these cells. Further, we evidenced that RPL6 siRNA down-regulated cyclin E expression
in SGC7901 and AGS cells. Taken together, these data suggested that RPL6 was over-expressed in human gastric tissues and
caused poor prognosis. Down-regulation of RPL6 could suppress cell growth and cell cycle progression at least through
down-regulating cyclin E and which might be used as a novel approach to gastric cancer therapy.
Citation: Wu Q, Gou Y, Wang Q, Jin H, Cui L, et al. (2011) Downregulation of RPL6 by siRNA Inhibits Proliferation and Cell Cycle Progression of Human Gastric
Cancer Cell Lines. PLoS ONE 6(10): e26401. doi:10.1371/journal.pone.0026401
Editor: Xin-yuan Guan, The University of Hong Kong, China
Received August 7, 2011; Accepted September 26, 2011; Published October 17, 2011
Copyright:  2011 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by grants from the National Basic Research Program of China (No. 2010CB732400, No. 2010CB529300), and the
National Natural Science Foundation of China (No. 30801349). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: daimingfan@fmmu.edu.cn (DF); shiyquan@fmmu.edu.cn (YS)
. These authors contributed equally to this work.
Introduction
Gastriccancer,withhighmorality,wasoneofthemostmalignant
cancers in Asian countries. Its occurrence was a process with multi-
factors and multi-steps, involved in alterations in many molecules,
including activation of proto-oncogenes, inactivation of tumor-
suppressor genes, alterations in cell cycle related proteins and so on.
In the past decade, a great number of proto-oncogenes and tumor-
suppressor genes have been found. In spite of the sizable number of
genes already described, new genes with oncogenic potential or
tumor-suppressing activities are still being identified. However, the
molecular mechanism of gastric carcinogenesis remains unclear.
Ribosome is essential for protein synthesis in all cells, which is
constituted of ribosomal RNAs (rRNAs) and ribosomal proteins
(RPs). Many RPs also play various roles that are independent of
protein biosynthesis, which is called extra-ribosomal function [1].
Increasing more research demonstrated that disorder of protein
translation participated in tumorigenesis and many ribosomal
proteins were dysfunctional in tumors, but the mechanisms were
still unknown [2]. It has been proposed that many RPs act as
haploinsufficient tumor suppressors in fish and many RPs genes
might also be oncogenes in human kind [3]. The earliest report on
relationships between RPs and tumors was published in 90 s of the
20
th century, which demonstrated the association of RPS19 with
colon carcinoma progression and differentiation [4].Thereafter,
more and more RPs were found dysfunctional in tumors, such as
high expression of RPL19 in breast tumors [5], over-expression of
RPL7a and RPL37 in prostate-cancer tissue samples [6], higher
expression of RPL15 in esophageal cancer [7], RPs as early
detection marker of human squamous cell carcinoma of the
uterine cervix [8], and over-expression of RPL36a associated with
cellular proliferation in hepatocellular carcinoma [9] and so on.
Reports regarding the association of RPs with carcinogenesis were
still increasing [2,10]. However, the exact roles of RPs in tumor
development are diverse and still need further clarification.
Previously, we analyzed the mRNA profiles of a human gastric
cancer cell line SGC7901 and its multidrug-resistant variant
SGC7901/VCR by differential displayed PCR and suppression
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the over-expressed genes in SGC7901/ADR compared to
SGC7901, which was further confirmed by RT-PCR and
Northern blot analysis [13]. Subsequent studies revealed that up-
regulation of RPL6 protected gastric cancer cells from adriamycin-
induced apoptosis and enhanced the resistance of gastric cancer
cells to multiple chemotherapeutic drugs, including vincristine,
adriamycin, etopside, cisplatin and 5-fludrouracil [13]. These data
indicated that RPL6 could promote the malignant phenotypes of
gastric cancer cells, which led us to conduct the subsequent study
to further explore the exact role of RPL6 in carcinogenesis and
development of gastric cancer. Then we discovered that
genetically up-regulation of RPL6 in GES cells could accelerate
the growth and enhance in vitro colony forming ability of GES
cells while down-regulation of RPL6 could exhibit the opposite
results. Moreover, up-regulation of RPL6 could promote G1 to S
phase transition of GES cells. Further study demonstrated that
RPL6 up-regulated cyclin E expression in GES cells [14]. Taken
together, these data suggested that RPL6 could promote the
malignant phenotypes of gastric cancer cells and RPL6 might play
an oncogenic role in the tumorigenesis and development of gastric
cancer, which led us to conduct the present study to explore the
potential role of RPL6 in gene therapy of gastric cancer and might
be used as a novel approach to gastric cancer therapy.
Results
RPL6 and cyclin E expression in human gastric cancer
specimens and matched adjacent non-neoplastic tissues
To explore the relationships between RPL6 and cyclin E
expression with the development of gastric cancer, we detected
RPL6 and cyclin E expression in human gastric cancer tissues and
matched adjacent non-neoplastic tissues by immunohistochemical
staining. The results revealed that RPL6 and cyclinE localized
almost in cytoplasm and only occasionally in nuclei in gastric cancer
cells (Fig. 1A). Further analysis discovered that the positive ratio
(including specimens that stained) of RPL6 was 84% (46 of 55
patients) while the positive ratio of cyclin E was 75% (41 of 55
patients) in human gastric cancer specimens. The positive ratio of
both RPL6 and cyclin E was 70% (38 of 55 patients) while the
negative ratio (including specimens that did not stain) of both RPL6
and cyclin E was 11% (6 of 55 patients) in human gastric cancer
specimens.ThepositiveratioofbothRPL6andcyclinEwas18%(8
of 55 patients) in matched adjacent non-neoplastic tissues (data not
shown).AsforthedifferencesbetweenRPL6expressionand cyclinE
expression in human gastric cancer specimens, there was no
difference. The present study demonstrated that RPL6 and cyclin E
expressions in human gastric cancer specimens were relative
(Fig. 1B, p,0.05), which may play a con-generous role in the
development of gastric cancer and RPL6 and cyclin E may serve as
a biomarker for gastric cancer diagnosisand a gene target for gastric
cancer therapy. At the end of follow up, survival time of the patients
were analyzed by Kaplan- Meier method and the results revealed
that during patients that were followed up, patients with both RPL6
positive and cyclin E positive showed a shorter survival time and
poorer prognosis than those with both RPL6 negative and cyclin E
negative expression, or those with RPL6 positive and cyclin E
negative or with RPL6 negative and cyclinE positive expression
respectively (Fig. 2 A, p,0.01), which can be revealed that patients
with both RPL6 positive and cyclin E positive showed poor
prognosis. It is also demonstrated that patients with RPL6 negative
expression showed longer survival time than RPL6 positive ones
(Fig. 2B, p,0.01), and patients with cyclin E positive expression
showed poor prognosis (Fig. 2C, p,0.01). Therefore, a conclusion
can be drawn that RPL6 may served as a biomarker for evaluating
the prognosis of gastric cancer patients.
Expression of RPL6 in gastric cancer cell lines and its
derivates
To further explore the potential role of RPL6 in gene therapy of
gastric cancer, SGC7901 and AGS cells were transfected with
RPL6-specific siRNA and the mixed pool of G418-resistant cell
variants was produced. The G418-resistant variants harboring
RPL6-specific siRNA were accordingly named as SGC7901-
siRPL6-1, AGS-siRPL6-1 and SGC7901-siRPL6-2, AGS-siRPL6-
2. The G418-resistant cells harboring scramble siRNA plasmids
were designed as SGC7901-siControl and AGS-siControl respec-
tively. As shown in Figure 3A, RPL6 expression was significantly
down-regulated in SGC7901-siRPL6-1, AGS-siRPL6-1 and
SGC7901-siRPL6-2, AGS-siRPL6-2 cells compared with parental
Figure 1. RPL6 and cyclinE expression in human gastric cancer specimens and matched adjacent non-neoplastic tissues. A.
Representative images shown are negative immunohistochemical control of IgG (a) and positive immunohistochemical staining of RPL6 (b) and cyclin
E (c) in the same gastric cancer tissues (magnification6200). B. Statistical analysis of data on the correlation between RPL6 and cyclinE expression in
human gastric cancer specimens. (p,0.05).
doi:10.1371/journal.pone.0026401.g001
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2 and AGS-siRPL6-2 showed more effective inhibitory results,
which indicated that the SGC7901-siRPL6-2 and AGS-siRPL6-2
cells could be used as a good cell model to clarify the potential role
of RPL6 in gene therapy of gastric cancer for clinic.
Downregulation of RPL6 suppress gastric cancer cell
growth in vitro
To study whether down-regulation of RPL6 expression could
inhibit the growth of SGC7901 and AGS cells, parental cells,
control cells and their variants were seeded into culture plates and
theirgrowthwasmonitoredeverydaywith MTTassay.Asindicated
by the growth curves inFigure 3B,control(SGC7901-siControland
AGS-siControl) cells showed a similar growth rate to parental
(SGC7901 and AGS) cells respectively, whereas SGC7901-siRPL6-
1, AGS-siRPL6-1 and SGC7901-siRPL6-2, AGS-siRPL6-2 cells
exhibited lower growth rate than Control cells, and SGC7901-
siRPL6-2, AGS-siRPL6-2 cells showed the lowest growth rate
(Fig. 3B, p,0.05). The anchorage-independent growth of these cells
was further analyzed with soft agar colony formation assay. It was
revealed that SGC7901-siRPL6-1, AGS-siRPL6-1 and SGC7901-
siRPL6-2, AGS-siRPL6-2 cells produced much less cell colonies in
soft agarthantheirparentalcellsandcontrolcells(Fig.3C,p,0.05),
cells named with SGC7901-siRPL6-2 and AGS-siRPL6-2 pro-
duced the least colonies. These data suggested that down-regulation
of RPL6 could suppress gastric cancer cell growth and inhibit the
colony formation ability of SGC7901 and AGS cells.
RPL6 siRNA inhibited tumorigenesis of gastric cancer
cells in vivo
To further confirm the effects of RPL6 on tumorigenesis of gastric
cancer, tumor formation assay was performed in nude mice.
SGC7901, AGS and SGC7901-siRPL-2, AGS-siRPL6-2 cells were
subcutaneously inoculated into the right or left upper back of athymic
nude mice at a single site. (Fig. 4A and C) Four weeks later, mice were
killed and the transplanted tumors were excised and tumor sizes were
evaluated (Fig. 4B and D, p,0.05). There was a significant decrease
of sizes of xenografts in RPL6 down-regulated cells. These data
indicated that knock-down of RPL6 could suppress gastric cancer cell
tumorigenesisinvivoand RPL6 mayplaya keyroleinpromotingthe
malignant growth of gastric cancer cells in vivo.
RPL6 decelerated G1-S phase transition of SGC7901 cells
To uncover the mechanisms underlying the suppressive role of
RPL6 in gastric cancer cell growth, the effects of RPL6 on cell
cycle distribution of SGC7901 cells were analyzed (Fig. 5A). As
shown in Figure 5B, SGC7901-siRPL6-1 cells showed slightly
increased percentage of G1 phase and decreased percentage of S
phase, while SGC7901-siRPL6-2 cells displayed significantly
increased percentage of G1 phase and decreased percentage of S
phase (P,0.05) compared with parental cells and Control cells.
These indicated that RPL6-specific siRNA could decelerate the
G1-S transition of SGC7901 cells.
RPL6 down-regulated expression of cyclin E in gastric
cancer cells at the protein level
It is well known that G1-S progression is controlled by cyclin D/
CDK4 and cyclin E/CDK2 complexes, which are regulated by
INK4 family members, p21 and p27, respectively. The expression
of these regulators in SGC7901 and AGS cells and its variants
were determined by Western Blot analysis. As indicated in
Figure 6, expression of cyclin E was significantly down-regulated
in SGC7901-siRPL6-2 and AGS-siRPL6-2 cells. Expressions of
CDK2, p16, p21 and p27 were unchanged in SGC7901 and AGS
cell variants. These data suggested that down-regulation of RPL6
decreased the expression of cyclin E in SGC7901 and AGS cells,
which might delineate the potential role of RPL6 and cyclin E in
the development of gastric cancer and RPL6 may used as a gene
target for gastric cancer in the clinic.
Discussion
The present study demonstrated that RPL6 and cyclin E were
over-expressed in gastric cancer tissues and there is a positive
Figure 2. Upregulation of RPL6 and Cyclin E expression
shorten patients’ survival time after followed up. A. Patients
with both RPL6 andCyclinE positive, RPL6 positive andCyclinE negative,
RPL6 negative and Cyclin E positive, both RPL6 and Cyclin E negative. B.
Patients with RPL6 positive and negative. C. Patients with Cyclin E
positive and negative. p,0.01 vs both RPL6 and Cyclin E positive and the
corresponding control; * p,0.01 vs RPL6 positive and RPL6 negative.
doi:10.1371/journal.pone.0026401.g002
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results revealed that patients with RPL6 negative expression
showed longer survival time than those with RPL6 positive
expression, which suggested that RPL6 positive patients showed
poor prognosis. Further research demonstrated that down-
regulation of RPL6 by RPL6-specific siRNA inhibited the
proliferation and anchorage-independent growth of gastric cancer
cell lines in vitro, repressed cell cycle progression and suppressed
cyclin E expression, Moreover, knockdown of RPL6 by RPL6-
specific siRNA suppressed tumor formation ability of gastric
cancer cells in vivo.
In our previous study, differentially expressed genes associated
with the multidrug resistance of gastric cancer cells were isolated
using differential display RT-PCR and subtractive hybridization
[11,12]. RPL6, a component of the large subunit of ribosome, was
thus isolated as a clone over-expressed in multidrug-resistant
gastric cancer cells [11]. It was demonstrated that RPL6 could
protect gastric cancer cells from chemotherapeutic drug-induced
apoptosis [13]. These data suggested that RPL6 might involve in
the regulation of the malignant phenotype of gastric cancer.
Further study was designed to explore the role of RPL6 in the
tumorigenesis and development of gastric cancer, and results
suggested that up-regulation of RPL6 accelerated growth and in
vitro colony forming ability of GES cells whereas down-regulation
of RPL6 exhibited opposite results. Also, up-regulation of RPL6
accelerated G1 to S phase transition of GES cells at least through
up-regulation of cyclin E expression while down-regulation of
RPL6 showed opposite results [14]. Taken together, these data
suggested that RPL6 might play an oncogenic role in tumorigen-
esis and development of gastric cancer and might serve as a novel
approach to gene therapy of gastric cancer.
Nowadays, increasing more patients died of cancer because of
the malignant phenotypes of them. Cancer therapy disturbed
people worldwide. Besides chemotherapy and surgery treatment,
gene therapy is a novel and promising cancer treatment. One of
the most commonly used methods for gene therapy is RNA
interference (RNAi). RNAi, a highly conserved gene silencing
mechanism plays an important role in the regulation of gene
expression. Gene silencing by a post-transcriptional mechanism
involving homologous double-stranded RNA was first discovered
in artificial systems where double strand RNA (dsRNA) was
introduced through injection or by expression of transgenic
constructs. This phenomenon occurs by small interfering RNA
(siRNA) in the cytoplasm of mammalian cells. In siRNA
technology, two delivery mechanisms were considered, direct
delivery of synthetic siRNA nucleotide and introduction of a
plasmid DNA (pDNA) encoding a short hairpin construct (shRNA)
that would be enzymatically degraded into siRNA [15]. SiRNA
played its inhibitory roles by matching with the sequences of
mRNA and inhibited the consequent mRNA expression and
Figure 3. Downregulation of RPL6 represses gastric cancer cell growth in vitro. A. Detection of RPL6 in SGC7901/AGS, SGC7901/AGS-
siRPL6-1,SGC7901/AGS-siRPL6-2, SGC7901/AGS-siRPL6-Control cells. b-actin was detected as a loading control. B. The growth curves of SGC7901/AGS
cell variants with down-regulated RPL6 were determined. The proliferation of SGC7901/AGS cell derivates was monitored with MTT assay as
described in ‘‘Materials and Methods’’ and their growth curves were plotted. Error bars correspond to mean 6 SD. P,0.05 compared with control
cells. C. Colony formation ability of SGC7901/AGS cell variants with down-regulated RPL6 was determined with soft agar colony formation assay as
described in ‘‘Materials and Methods’’. Values represent the mean 6 SD of triplicates in each experiment. Shown are representative of at least three
separate experiments. (p,0.05).
doi:10.1371/journal.pone.0026401.g003
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and more scientists have discovered that knocked down gene
expression by siRNA could significantly suppress tumor growth
and metastasis. X-linked inhibitor of apoptosis protein (XIAP), an
important member of the inhibitors of apoptosis protein (IAP)
family, is involved in control of cell division, cell proliferation and
inhibition of apoptosis [16,17]. Down-regulation of XIAP by
siRNA could significantly suppress proliferation of tumor cells and
Figure 4. Down-regulation of RPL6 inhibits tumorigenesis in vivo. A. SGC7901 cells stably transfected with RPL6-specific siRNA1 (left) or with
RPL6-scramble siRNA were injected into nude mice. B. Four weeks after the injection, mice were photographed and killed. Tumor sizes were
measured. Error bars indicate mean 6 SD. p,0.05 compared with the control group. C. SGC7901 cells stably transfected with RPL6-specific siRNA2
(left) or with RPL6-scramble siRNA were injected into nude mice. D. Four weeks after the injection, mice were photographed and killed. Tumor sizes
were measured. Error bars indicate mean 6 SD. p,0.05 compared with the control group.
doi:10.1371/journal.pone.0026401.g004
Figure 5. Cell cycle analysis of SGC7901 cells and its derivates. A. SGC7901 and its derivates in log phase were harvested and subjected to
cell cycle analysis. The cell cycle phase distribution was evaluated by FACS. Shown are representative images of four separate experiments. B. Cell
cycle distribution of SGC7901, SGC7901-siRPL6-1, SGC7901-siRPL6-2 and SGC7901-siRPL6Control cell lines. The cell cycle distribution was calculated
and expressed as mean 6 SD of four separate experiments. p,0.05.
doi:10.1371/journal.pone.0026401.g005
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pontin (OPN) protein, which was over-expressed in the majority of
gastric cancer patients and associated with its pathogenesis, played
an important role in the proliferation, invasion, metastasis and
survival of gastric cancer [20]. Then down-regulation of OPN by
OPN-specific siRNA significantly inhibited the growth, migration
and invasion of gastric cancer cells [21]. CML66, a novel tumor
antigen which played an oncogenic role, was over-expressed in a
majority of cancer cell lines and cancers [22], knocking down its
expression by CMl66-specific siRNA significantly inhibited
proliferation, invasion and metastasis of HeLa cells both in vivo
and in vitro experiments [23]. FABP5, which encodes cutaneous
fatty acid binding protein (C-FABP), is up-regulated in prostate
cancer and acts as a putative oncogene. Down-regulation of
FABP5 by FABP5-specific siRNA effectively inhibited prostate
cancer cell growth in nude mice [24]. Moreover, when ribosomal
protein RPS13 which enhanced gastric cancer cell line SGC7901
growth was knocked down by RPS13-specific siRNA, it signifi-
cantly inhibited SGC7901 cell growth and colony forming ability
in vitro and suppressed tumor formation ability in nude mouse
[25]. Previous research also found that systemic delivery of siRNA
via atelocollagen, which specifically targets tumors, is safe and
feasible for cancer therapy in prostate cancer [26]. Therefore,
evidence above suggested that siRNA, by inhibiting gene
expression could be a novel approach to cancer therapy and
make gene therapy of cancer feasible for clinical treatment.
In the present study, expressions of RPL6 and cyclin E in gastric
cancer tissues and the matched adjacent non-neoplastic tissues
were detected and the results indicated that RPL6 and cyclin E
showed higher expression in gastric cancer tissues than in matched
adjacent non-neoplastic tissues. Furthermore, there is a correlation
between RPL6 and cyclin E expression in gastric cancer tissues,
which suggested that they may play a con-generous role in the
development of gastric cancer and RPL6 might serve as a
biomarker for gastric cancer diagnosis. Follow up results
demonstrated that patients with both RPL6 positive and cyclin
E positive expressions showed a shorter survival time and poorer
prognosis than the corresponding control and also indicated that
patients with RPL6 negative expression showed longer survival
time and better prognosis than patients with RPL6 positive
expression, which suggested that RPL6 may served as a biomarker
for gastric cancer prognosis and a gene target for gastric cancer
therapy in clinic.
To further explore the potential feasibility of RPL6 as gene
therapy target of gastric cancer in clinic, we knocked down RPL6
expression in SGC7901 and AGS cells by RPL6-specific siRNA,
results showed that down-regulation of RPL6 in gastric cancer
parental cell lines (SGC7901 and AGS) effectively inhibited cell
growth and in vitro colony forming ability. Further, cell cycle
analysis indicated that down-regulation of RPL6 decelerated G1 to
S phase of gastric cancer cells. Western blot analysis demonstrated
that RPL6 inhibited cell cycle progression through down-
regulation of cyclin E. Tumor formation experiments in nude
mice suggested that down-regulation of RPL6 could suppress
tumor formation in vivo.
Cyclin E, a key cell cycle protein that played key roles in G1-S
transition was in disorder in many different tumors
[27,28,29,30,31]. Previous research demonstrated that cyclin E
was an important molecule in tumorigenesis. In the present study,
we discovered that cyclin E expression, together with RPL6 was
higher in human gastric cancer tissues than that in matched
adjacent non-neoplastic tissues, which suggested the role of cyclin
E played in the development of gastric cancer. Further research
demonstrated that RPL6 affected cell growth by regulating cyclin
E, which showed that high expression of cyclin E accelerated cell
growth while low expression of cyclin E decelerated cell
proliferation. Cyclin E and RPL6 may play con-generous roles
in the development of gastric cancer.
In conclusion, the present study demonstrated that RPL6 and
cyclinE expression were associated with each other in gastric
cancer tissues and they might play con-generous roles in the
development of gastric cancer, which suggested that RPL6 may
used as a diagnostic tool in gastric cancer. Follow up data analysis
demonstrated that patients with RPL6 negative expression showed
longer survival time and better prognosis than patients with RPL6
positive expression postoperatively, which suggested that RPL6
served as a biomarker for gastric cancer prognosis and a novel
gene target for gastric cancer therapy. Further study indicated that
down-regulation of RPL6 expression by RPL6-specific siRNA
inhibited SGC7901 cell growth and in vitro colony formation
ability, decelerated SGC7901 cell G1 to S phase transition, and
suppressed tumor formation in vivo. In conclusion, our present
study confirmed that RPL6 siRNAs might be used as a novel
approach to gastric cancer therapy for clinic.
Materials and Methods
Ethics Statement
For tissue specimens, all patients were informed consent to use
excess pathological specimens for research purposes. The
protocols used in this study were approved by the hospital’s
Protection of Human Subjects Committee. The use of human
Figure 6. Detection of cell cycle-related proteins in SGC7901 cells. The expression of cyclin E, CDK2, p21, p16 and p27 in SGC7901 and AGS
cell variants with down-regulated RPL6 was determined by Western blot using the corresponding antibodies. b-actin was detected as a loading
control.
doi:10.1371/journal.pone.0026401.g006
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Fourth Military Medical University and was conformed to the
Helsinki Declaration, and to local legislation. Patients offering
samples for the study signed informed consent forms. For animal
research, all procedures for animal experimentation were
performed in accordance with the Institutional Animal Care and
Use Committee guidelines of the Experiment Animal center of the
Fourth Military Medical University. The approval ID for using the
animals was No. 10218 by Experiment Animal Center of the
Fourth Military Medical University.
Tissue specimens and cell lines
Tissue specimens embedded with paraffin were collected from
55 patients with gastric cancer who underwent gastrectomy in our
hospital between 2004 and 2009. All cases of gastric cancer and
adjacent non-tumor tissues were diagnosed clinically and patho-
logically. Data on clinicopathological features and prognoses of the
patients were collected and analyzed retrospectively. A total of 55
patients were followed up until the end of the year 2009 and two of
them were lost during the follow up period. Human gastric
adenocarcinoma cell line SGC7901 was obtained from the
Academy of Military Medical Science, AGS was obtained from
the Shanghai Cell Bank (Shanghai, China). The two cell lines were
preserved in our institute. All the cell lines were maintained in
RPMI1640 (Invitrogen, Carlsbad, CA) supplemented with 10%
heat-inactivated fetal calf serum (FCS) at 37uC with 5% CO2 in a
humidified incubator (Forma Scientific, Marietta, OH).
Immunohistochemistry and Immunohistochemical
scoring
Deparaffinized and rehydrated sections were washed in fresh
water for 10 minutes. Heat-induced antigen retrieval was
performed for 20 minutes at 95uC with 10 mM citrate sodium
buffer (PH 6.0). After the slides were cooled at room temperature
for 40 minutes, they were blocked in 3% hydrogen peroxide for
20 minutes and then in normal goat serum confining liquid for
40 minutes. After this, they were allowed to react over night at
4uC with primary antibodies for IgG, RPL6 and cyclinE (Santa
Cruz). After rewarming for 40 minutes, they were then reacted
with second antibodies (Zhongshan Goldenbridge Biotechnology
CO.LTD) for another 40 minutes at room temperature. Then the
products were developed with 3,39-diaminobenzidine and coun-
terstained with haematoxylin. Scoring was completed by a
specialist pathologist and a scientist who were blinded to the
clinical and pathologic information. In case of discrepancy, a
consensus was reached by conferencing. The proportions of
positive cells (0 to +3) and the staining intensities (0 to +3) were
evaluated separately at a magnification of 6200. The former was
calculated by counting the number of stained tumor cells among
the total number of tumor cells, for example, when 25% of total
cells were stained, the proportion score was +1, and 50% equals to
+2, 75% equals to +3, 0% equals to 0. The intensity scoring was
evaluated by the color of stained tumor cell nucleus, specifically,
score 0 means achromatic, +1 means amber, +2 means yellow, and
+3 means brown. Combined scoring +1,+2 were defined
‘‘negative’’, and +3,+6 were considered ‘‘positive’’.
Plasmid construction and transfection
Two pairs of hairpin small interfering RNA (siRNA) oligos for
RPL6 were designed according to the siRNA design guidelines of
TaKaRa Biotechnology Co., Ltd. Compare target sequences to
the human genome database in a BLAST search to eliminate from
consideration any target sequence with 21 base pairs of homology
contiguous to other coding sequences. For oligo-1, sense: 59-GA-
TCCGGAGAAGGTTCTCGCAACTTTCAAGAGAAGTTG-
CGAGAACCTTCTCCTTTTTTGGAAA-39, antisense: 59AG-
CTTTTCCAAAAAAGGAGAAGGTTCTCGCAACTTCTCT-
TGAAAGTTGCGAGAACCTTCTCCG-39; for oligo-2, sense:
59-GATCCGTCGAGTTCCTCTACGAAGATTCAAGAGAT-
CTTCGTAGAGGAACTCGATTTTTTGGAAA-39, antisense:
59-AGCTTTTCCAAAAAATCGAGTTCCTCTACGAAGAT-
CTCTTGAATCTTCGTAGAGGAACTCGACG-39; A scram-
ble DNA duplex was also designed as control, for oligo-1, sense:
59-GATCCGGTGAGATCTTCGACACAGTTCAAGAGACT-
GTGTCGAAGATCTCACCTTTTTTGGAAA-39, antisense:
59-AGCTTTTCCAAAAAAGGTGAGATCTTCGACACAGT-
CTCTTGAACTG TGTCGAAGATCTCACCG-39. For an-
nealing to form DNA duplexes, 0.01 M each of sense and
antisense oligos were used. The duplexes were diluted and then
ligated with pSilencer3.1-H1 neo vector (TaKaRa Biotechnolo-
gy(Dalian)Co., Ltd). The products were transformed into DH5a-
competent cells. Ampicillin-resistant colonies were chosen, iden-
tified by restriction digestion, and further confirmed by DNA
sequencing. According to the manufacturers’ instructions, siRNA
plasmids of RPL6 were transfected into SGC7901 cells using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA), respec-
tively. Twenty-four hours after transfection, G418 (400 mg/ml)
was added into the culture medium for establishing stable clones.
The mixed clones were expanded for an additional 2 months. The
SGC7901 and AGS cells (also called parental cells) stably
expressing exogenic RPL6 were named as SGC7901-siRPL6-1,
AGS-siRPL6-1, and SGC7901-siRPL6-2, AGS-siRPL6-2. And
cells transfected with siControl were named as SGC7901-siRPL6
Control and AGS-siRPL6 Control (also called control cells).
Cell proliferation assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT) assay was performed to evaluate the effect of RPL6 on
cell proliferation as previously described [32]. The absorbance at
490 nm (A490) of each well was read on a microplate reader
BP800 (Biohit, Helsinki, Finland). Each experiment was per-
formed in quadruplicates and was repeated 3 times.
Soft agar colony formation assays
Soft agar colony formation assay was used to determine
anchorage-independent cell growth potential. Twelve well plates
were filled with 0.5 ml of 0.5% noble agar (Invitrogen) in
RPMI1640 supplemented with 10% calf serum as a bottom layer
and allowed to solidify at 4uC overnight. A total of 200 cells were
suspended in 0.25 ml of 0.3% agarose and seeded on the bottom
agar. Cell culture plates were maintained for 2 weeks in a CO2
incubator. The number of colonies was counted under a
microscope.
Tumorigenicity in nude mice
Tumour formation was carried out to assess the effects of RPL6
on tumorigenicity in vivo. BALB/c nude mice of 4 to 6 weeks were
provided by Shanghai Cancer Institute and housed in micro-
isolator cages under positive air pressure, and maintained at a
constant temperature (22uC) and humidity for the tumorigenicity
study. Approximately 3610
6 cells at log phase were collected and
injected subcutaneously into the upper back of BALB/c nude
mice. At least three nude mice were used for each group. The mice
were killed 4 weeks later and tumor weight of each mouse was
evaluated. All procedures for animal experimentation were
performed in accordance with the Institutional Animal Care and
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Fourth Military Medical University.
Cell cycle analysis
For analysis of cell cycle phase distribution, SGC7901 and its
variants at log phase were harvested and washed twice with ice-
cold PBS. Cell pellets were fixed in 70% ethanol, treated with
RNase A (Boehringer Mannheim, Indianapolis, IN) and stained
with propidium iodide (Sigma-Aldrich, St. Louis, MO). DNA
contents were measured with a flow cytometer (FACS; Becton
Dickinson, San jose, CA).
Western blot analysis
Whole cell lysates were prepared in lysis buffer containing
50 mM Tris PH 7.2, 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% sodium dodecyl sulfate, 500 mM NaCl, and 10 nm
MgCl2 with 10 mg/ml leupeptin, 10 mg/ml aprotinin, and 1 mM
PMSF. The total proteins were resolved over 12% SDS-PAGE
and transferred to nitrocellulose membranes (Immobilin-P; Milli-
pore, Bedford, MA). The membranes were blocked with 5%
nonfat milk at room temperature for 1 hour and then incubated
with primary antibodies at 4uC overnight, followed by incubation
with peroxidase-conjugated secondary antibodies for 2 hours at
room temperature. Immunoreactive bands were detected and
developed in ECL (enhanced chemiluminescence) system (Amer-
sham Pharmacia Biotechnology, Uppsala, Sweden) with X-ray
film. Antibodies against RPL6, cyclin E, CDK2, p16, p21, p27
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-b-actin was from Sigma (St. Louis, MO). Peroxidase-
conjugated goat anti-mouse and goat anti-rabbit IgG were
purchased from Boster (Wuhan, Hubei, China).
Statistical Analysis
Statistical analyses were performed using SPSS statistical
software (SPSS, Inc., Chicago, Illinois).Categorical variables were
compared with chi-square test, the survival of the patients were
evaluated by the Kaplan- Meier method, and the log-rank test was
used to compare the differences. Mann-Whitney U test and
Kruskal-Wallis H test were adopted for other data. Significance
was defined as P,0.05.
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